AXA IM Alts raises €1.9bn European Life Sciences Fund
AXA IM Alts has raised €1.9bn of equity to accelerate investments into the Life Sciences sector.
ADVERTISEMENT
Log in here to read the desired article.
ADVERTISEMENT
This author has not written his bio yet.
But we are proud to say that Thomas Gabrielczyk contributed 2207 entries already.
AXA IM Alts has raised €1.9bn of equity to accelerate investments into the Life Sciences sector.
Synaffix has nonexclusivey licensed its award-winning ADC technologies to Chinese ProfoundBio in an up to $246m deal
Mainz-based BioNTech is expanding its portfolio for cancer therapies with the neoantigen TCR Cell Therapy R&D pipeline and manufacturing site from Gilead Science subsidiary Kite Pharmaceuticals.
Coventry-based NanoSyrinx plc has raised £6.2m in seed financing to develop a new cell engineering tool for novel targeted therapeutic modalities.
As part of its ‘Clean Future’ strategy, Unilever NV has licensed enzyme technology from Arzeda Inc. to help rid detergent production of fossil carbon.
Oslo-based microbiome expert Bio-Me A/S has raised NOK10m in a new funding round.
This white paper explores the drug repurposing, where known clinical candidates or commercially approved molecules are evaluated for new targets and indications.
Early-stage venture capital investor Novalis Biotech has closed its Biotech Acceleration Fund at €25m to drive growth of translational medicine start-ups.
Swedish Cellink AB has announced a bid of $110m to take over all shares of Discover Echo Inc., 11% of which to be paid in newly issued shares.
The Thermo Scientific HyPerforma GXCore Bioprocess Controller is an innovative, compact, cost-effective, open-architecture controller built for research and process development applications.

